{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T20:39:30Z","timestamp":1764103170712,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jpba.2021.113946","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T06:20:21Z","timestamp":1612506021000},"page":"113946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Identification and structural elucidation of a new cetrorelix methylene dimer impurity in cetrorelix acetate by using LC-MS\/MS"],"prefix":"10.1016","volume":"197","author":[{"given":"Mingliang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huapeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heqing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanzhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingmin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2021.113946_bib0005","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0015-0282(16)38580-6","article-title":"Hypothalamic follicle-stimulating hormone (FSH) and luteinizing hormone (LH)-regulating hormone: structure, physiology, and clinical studies","volume":"22","author":"Schally","year":"1971","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.jpba.2021.113946_bib0010","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1399-3011.1994.tb00389.x","article-title":"Structural investigation of Cetrorelix, a new potent and long-acting LHRH antagonist","volume":"43","author":"Mulleri","year":"2010","journal-title":"Int. J. Pept. Protein Res."},{"key":"10.1016\/j.jpba.2021.113946_bib0015","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejpb.2004.10.005","article-title":"Development and in vitro evaluation of a liposome based implant formulation for the decapeptide Cetrorelix","volume":"59","author":"Grohganz","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jpba.2021.113946_bib0020","first-page":"287","article-title":"Results obtained in the treatment of prostate cancer patients with Zoladex","volume":"185A","author":"Williams","year":"1985","journal-title":"Prog. Clin. Biol. Res."},{"key":"10.1016\/j.jpba.2021.113946_bib0025","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejpb.2004.10.005","article-title":"Development and in vitro evaluation of a liposome based implant formulation for the decapeptide Cetrorelix","volume":"59","author":"Grohganz","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jpba.2021.113946_bib0030","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000234028","article-title":"Antagonistic analogs of luteinizing hormone-releasing hormone are mast cell secretagogues","volume":"80","author":"Morgan","year":"1986","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.jpba.2021.113946_bib0035","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/humupd\/6.4.322","article-title":"The LHRH antagonist Cetrorelix: a review","volume":"6","author":"Reissmann","year":"2000","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.jpba.2021.113946_bib0040","first-page":"142","article-title":"Cetrorelix, a potent LHRH-antagoni-st: Chemistry, pharmacology and clinical data","author":"Engel","year":"2002","journal-title":"Bioact. Pept."},{"key":"10.1016\/j.jpba.2021.113946_bib0045","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1399-3011.1988.tb01373.x","article-title":"New antagonists of LHRH II. Inhibition and potentiation of LHRH by closely related analogues","volume":"32","author":"Bajusz","year":"1988","journal-title":"Int. J. Pept. Protein Res."},{"key":"10.1016\/j.jpba.2021.113946_bib0050","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1073\/pnas.87.18.7100","article-title":"Prolonged inhibition of luteinizing hormone and testosterone levels in male rats with the luteinizing hormone-releasing hormone antagonist SB-75","volume":"87","author":"Bokser","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jpba.2021.113946_bib0055","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1073\/pnas.85.5.1637","article-title":"Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects","volume":"85","author":"Bajusz","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jpba.2021.113946_bib0060","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0015-0282(16)56932-5","article-title":"A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge","volume":"62","author":"Leroy","year":"1994","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.jpba.2021.113946_bib0065","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1530\/eje.0.1310280","article-title":"Seven-day administration of the gonadotropin-releasing hormone antagonist Cetrorelix in normal cycling women","volume":"131","author":"Sommer","year":"1994","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.jpba.2021.113946_bib0070","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/00912700022008937","article-title":"Pharmacokinetic-pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers","volume":"40","author":"Pechstein","year":"2000","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2021.113946_bib0075","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000125862","article-title":"Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75)","volume":"54","author":"Bokser","year":"1991","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.jpba.2021.113946_bib0080","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000126527","article-title":"Inhibitory effect of a highly potent antagonist of LH releasing hormone (SB-75) on the pituitary gonadal axis in the intact and castrated rat","volume":"58","author":"Ayalon","year":"1993","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.jpba.2021.113946_bib0085","unstructured":"U.S. Food and Drug Administration, Drugs@FDA, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2000\/21197lbl.pdf."},{"key":"10.1016\/j.jpba.2021.113946_bib0090","first-page":"1207","article-title":"Effects of cetrorelix versus ganirelix in gonadotropin-releasing hormone antagonist cycles for preventing premature luteinizing hormone surges and on clinical outcomes of IVF-ET cycles","volume":"39","author":"Zhang","year":"2019","journal-title":"J. South. Med. Univ."},{"key":"10.1016\/j.jpba.2021.113946_bib0095","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/pros.2990180307","article-title":"Histological changes in Dunning prostate tumors and testes of rats treated with LH-RH antagonist SB-75","volume":"18","author":"Szepeshazi","year":"1991","journal-title":"Prostate"},{"key":"10.1016\/j.jpba.2021.113946_bib0100","first-page":"107","article-title":"The application of peptide sequencing for characterization of cetrorelix and its related impurities","volume":"4","author":"Hooshfar","year":"2016","journal-title":"World J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2021.113946_bib0105","first-page":"43","article-title":"Development and validation of a reversed-phase HPLC method for assay of the decapeptide cetrorelix acetate in bulk and pharmaceutical dosage forms","volume":"13","author":"Hooshfar","year":"2014","journal-title":"Iran. J. Pharm. Res."},{"key":"10.1016\/j.jpba.2021.113946_bib0110","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bpobgyn.2018.06.010","article-title":"Conservative management of reproductive cancers. Ovarian protection during treatment, BEST","volume":"55","author":"Cui","year":"2019","journal-title":"Pract. Res. CL. OB."},{"key":"10.1016\/j.jpba.2021.113946_bib0115","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11596-012-0067-x","article-title":"Mechanisms of prostate atrophy after LHRH antagonist cetrorelix injection: an experimental study in a rat model of benign prostatic hyperplasia","volume":"32","author":"Yang","year":"2012","journal-title":"J. Huazhong Univ. Sci. Technol. Med. Sci."},{"key":"10.1016\/j.jpba.2021.113946_bib0120","unstructured":"EMEA, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cetrotide-epar-product-information_en.pdf."},{"key":"10.1016\/j.jpba.2021.113946_bib0125","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejogrb.2004.11.005","article-title":"A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: effect on safety and efficacy","volume":"120","author":"Xavier","year":"2005","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.jpba.2021.113946_bib0130","unstructured":"PMDA, https:\/\/www.info.pmda.go.jp\/go\/interview\/2\/530191_249940YD1028_2_003_1F.pdf."},{"key":"10.1016\/j.jpba.2021.113946_bib0135","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s10895-010-0674-5","article-title":"Fluorescence spectroscopic determination of the critical aggregation concentration of the GnRH antagonists Cetrorelix, Teverelix and Ozarelix","volume":"20","author":"Schneider","year":"2010","journal-title":"J. Fluoresc."},{"key":"10.1016\/j.jpba.2021.113946_bib0140","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/0959-8049(96)00138-4","article-title":"Pharmacological studies with cetrorelix (SB-75), a potent antagonist of luteinising hormone-releasing hormone","volume":"32","author":"Reissmann","year":"1996","journal-title":"Eur. J. Cancer"},{"year":"2007","series-title":"Injection Solution Comprising an LHRH Antagonist","author":"Horst","key":"10.1016\/j.jpba.2021.113946_bib0145"},{"year":"2016","series-title":"Pharmaceutical Form of Administration for Peptides, Methods for Its Production and Use","author":"Hors","key":"10.1016\/j.jpba.2021.113946_bib0150"},{"key":"10.1016\/j.jpba.2021.113946_bib0155","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/mas.1280140104","article-title":"The interpretation of collision-induced dissociation tandem mass spectra of peptides","volume":"14","author":"Papayannopoulos","year":"1995","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.jpba.2021.113946_bib0160","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00204-019-02393-x","article-title":"Evaluation of inhaled low dose formaldehyde induced DNA damage by liquid chromatography-tandem mass spectrometry","volume":"93","author":"Leng","year":"2019","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.jpba.2021.113946_bib0165","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1021\/op3000459","article-title":"Removal of acrolein from active pharmaceutical ingredients using aldehyde scavengers","volume":"16","author":"Ke\u00e7ili","year":"2012","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.jpba.2021.113946_bib0170","first-page":"1","article-title":"Determination of potential genotoxic impurity, 5-Amino-2-chloropyridine, in active pharmaceutical ingredient using the HPLC-UV system","volume":"0","author":"Soyseven","year":"2020","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jpba.2021.113946_bib0175","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.seppur.2012.09.028","article-title":"Selective scavenging of the genotoxic impurity methyl p-toluenesulfonate from pharmaceutical formulations","volume":"103","author":"Kecili","year":"2013","journal-title":"Sep. Purif. Technol."},{"key":"10.1016\/j.jpba.2021.113946_bib0180","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.chroma.2014.02.073","article-title":"Fast identification of selective resins for removal of genotoxic aminopyridine impurities via screening of molecularly imprinted polymer libraries","volume":"1339","author":"Kecili","year":"2014","journal-title":"J. Chromatogr. A"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521000583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521000583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:11:03Z","timestamp":1760001063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708521000583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":36,"alternative-id":["S0731708521000583"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2021.113946","relation":{},"ISSN":["0731-7085"],"issn-type":[{"type":"print","value":"0731-7085"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification and structural elucidation of a new cetrorelix methylene dimer impurity in cetrorelix acetate by using LC-MS\/MS","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2021.113946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113946"}}